Humanized Antibody Development

Humanized antibody development is a revolutionary approach that combines cutting-edge technologies, including computational modeling and bioinformatics, to accelerate the process of developing therapeutic antibodies. This approach allows for the generation of antibodies with improved efficacy, reduced immunogenicity, and enhanced safety profiles, leading to more successful clinical outcomes.


Our service employs a proprietary algorithm that integrates multiple factors, such as antibody structure, binding affinity, and potential immunogenicity, to guide the humanization process. This algorithm allows for the rapid screening and selection of candidate antibodies, saving significant time and resources.

Service Specifications

Details  Deliverables Turnaround Time
(Business Days)
Chimeric antibody construction
Antigen-antibody binding analysis
Top 5 humanized antibody variants and corresponding DNA sequences.
At least 1 variant with a binding affinity comparable to parental antibody.
Full report (PDF)
4-5 Months
Antibody model library construction
Phage/Yeast display antibody library construction
High-throughput antibody screening
Humanized antibody characterization and production

Feature Services Items

Humanized Antibody Development

  • Antibody Design and Engineering: Our team of experts utilizes state-of-the-art software tools to design and engineer humanized antibodies based on target specificity and therapeutic requirements.
  • Computational Analysis: We perform in-depth computational analysis to predict the antigen-antibody interactions, optimizing their binding affinity and specificity.
  • Virtual Screening: Our service includes a virtual screening of antibody libraries to identify potential candidates with improved binding properties and reduced immunogenicity.
  • Lead Optimization: We employ computational algorithms to guide the selection and optimization of lead antibody candidates for further development.

Further Service

  • Structural Analysis: We perform a comprehensive structural analysis of the target antibody, identifying key regions for humanization and optimizing its binding properties.
  • In Silico Modeling: We employ sophisticated molecular modeling techniques to evaluate and optimize the antibody's stability, solubility, and overall functionality.
  • Off-Target Analysis: Our service includes an off-target analysis to ensure the specificity and safety of the humanized antibody, minimizing the risk of unintended interactions.


  • Humanized Antibody Candidates: Our service delivers a comprehensive portfolio of humanized antibody candidates that possess improved therapeutic potential.
  • Molecular Docking Reports: We provide detailed reports on the binding interactions between the humanized antibody and its target, aiding in the understanding of the antibody's mechanism of action.
  • Immunogenicity Profiles: Our service delivers immunogenicity profiles, enabling the identification and removal of potential immunogenic regions to enhance the safety and efficacy of the antibody.


  • Experience: Our team has hands-on experience in humanized antibody design, screening, and production to ensure the success of our client's projects.
  • In Silico Design: Efficient and reliable antibody modeling and simulation from multiple antibody databases.
  • Guaranteed Affinity: Final constructs are guaranteed to be within threefold affinity after affinity maturation.

Why Choose Us?

Our humanized antibody development service leverages computational modeling and advanced algorithms to accelerate and enhance antibody design. With our expertise, cutting-edge technology, and tailored approach, we aim to deliver humanized antibodies with improved efficacy, and reduced immunogenicity. Contact us today to discuss your project requirements or schedule a consultation with our team of experts. Together, we can drive innovation and make a significant impact in the field of antibody therapeutics.


  1. Fu Y, Sun Y, Yi K, et al. Combination of Virtual Screening Protocol by in Silico toward the Discovery of Novel 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors. Frontiers in Chemistry, 2018, 6(6).
* For Research Use Only.